Roth Capital began coverage on shares of Seelos Therapeutics (NASDAQ:SEEL) in a research note issued to investors on Tuesday, BenzingaRatingsTable reports. The firm issued a buy rating and a $8.00 price target on the stock.
Separately, HC Wainwright started coverage on Seelos Therapeutics in a research report on Friday, May 10th. They set a buy rating and a $4.00 price objective for the company.
Shares of NASDAQ SEEL opened at $2.72 on Tuesday. Seelos Therapeutics has a 12-month low of $1.32 and a 12-month high of $17.40.
About Seelos Therapeutics
Seelos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company is focused on neurological and psychiatric disorders, including orphan indications. Its lead programs are SLS-002, an intranasal racemic ketamine for the treatment of suicidality in post-traumatic stress disorder and in depressive disorder; and SLS-006, a partial dopamine agonist for monotherapy in early stage Parkinson's disease patients.
Further Reading: How to read a candlestick chart
Receive News & Ratings for Seelos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seelos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.